



EDUCATION IS THE BEST MEDICINE®

4325 Alexander Drive
Alpharetta, Georgia 30022-3740, USA

Imedex® is committed to environmental excellence.
This publication is printed on FSC-certified paper, which is
acid-free and elemental chlorine-free, and contains 50%
recycled content including 25% post-consumer waste.



5th International Congress on Myeloproliferative Diseases and Myelodysplastic Syndromes

November 5-7, 2009 - New York, New York
New York Marriott at The Brooklyn Bridge

Important Dates

- Abstract Submission Deadline**..... August 18, 2009
- Discounted Registration Deadline**..... September 1, 2009
- Abstract Notifications Mailed**..... September 15, 2009
- Abstract Presenter Registration Deadline**..... October 22, 2009
- Regular Registration Deadline**..... October 29, 2009
- Presentation Dates**..... November 5-7, 2009

3 WAYS TO LEARN: Visit www.imedex.com to learn more.



PRINT materials are produced by Imedex for your reference needs



ONLINE products are produced by Imedex in 6 user-friendly formats



LIVE meetings are produced by Imedex in 15 countries

5th

International Congress on Myeloproliferative Diseases and Myelodysplastic Syndromes



November 5-7, 2009 - New York, New York
New York Marriott at The Brooklyn Bridge

Chair and Convener:

Richard T. Silver, MD, FACP
Weill Cornell Medical College
New York, New York

Co-Chair:

Jerry L. Spivak, MD, FACP
Johns Hopkins University
Baltimore, Maryland

2nd Announcement and Call for Abstracts



5th International Congress on Myeloproliferative Diseases and Myelodysplastic Syndromes

Dear Colleague,

It is our pleasure to invite you to join us at **the 5th International Congress on Myeloproliferative Diseases and Myelodysplastic Syndromes**. The 2009 Congress, which will be held November 5-7 at the New York Marriott at the Brooklyn Bridge, promises to be our most exciting and interactive meeting yet!

Since the inaugural Congress in 2001, this meeting has grown to nearly 600 attendees and has become the premier forum for discussion on the latest advances in myeloproliferative diseases and myelodysplastic syndromes. It allows attendees a forum to update their knowledge in the field, confirm their current practices and receive valuable take-home information on exciting new screening and staging modalities, management approaches and emerging treatment options.

Guided by the expertise of the leaders in the fields of molecular biology, pathology, immunology, and translational and clinical research, this Congress promises to be a stimulating, interactive forum for attendees from all relevant medical specialties. We will focus on the most recent updates and debates centered around polycythemia vera, essential thrombocythemia, myelofibrosis, chronic myeloid leukemia and myelodysplasia.

With its diverse mix of oncologists, hematologists, surgeons, and pathologists, this will be a great place to interact with your colleagues and learn from internationally renowned faculty.

We look forward to welcoming you in November to New York as the Fall brings its special beauty to this exciting international city!

Sincerely,

Richard T. Silver, MD, FACP
Chair and Convener

Jerry L. Spivak, MD, FACP
Co-Chair

November 5-7, 2009 - New York, New York
New York Marriott at The Brooklyn Bridge

Continuing Medical Education



Imedex, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Imedex, LLC designates this educational activity for a maximum 17.75 of AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Who Should Attend

This educational Congress is specifically designed for hematologists, internists, oncologists and other physicians, physicians-in-training, and healthcare professionals (nurses, pharmacists) interested in and/or involved in the care of patients with myeloproliferative diseases and myelodysplastic syndromes.

Corporate Support

The following companies have provided an educational grant in support of this Congress:

Bronze



Bristol Myers Squibb
Company



Several options are available to companies interested in supporting this Congress. For more information, please contact Imedex at +1 (770) 751 7332, or by email at cme@imedex.com.

Objectives

After completion of this educational activity, participants should be able to:

- Review the classification and pathogenesis of myelodysplastic diseases
- Discuss current best practices in the treatment of MDS
- Comment on novel drugs in MDS, with a focus on management of iron overload
- Review new prognostic classifications and their relevance to allogeneic transplantation in primary myelofibrosis
- Discuss novel markers and therapies beyond JAK2 in myelofibrosis
- Review important genetic abnormalities in myeloproliferative disorders
- Comment on the clinical significance of mutations in polycythemia vera
- Identify the importance of cerebral circulation in outcomes related to polycythemia vera
- Discuss molecular drug targets in myeloproliferative disorders
- Review risk factors for thrombosis in MPDs
- Review the most current updates in the biology and pathogenesis of CML
- Improve response monitoring and overcome drug resistance to improve CML outcomes
- Review the management of CML in pregnancy
- Discuss second and third generation tyrosine kinase inhibitors and their existing and future positioning within the current treatment armamentarium
- Review treatment of accelerated and blast phase CML disease
- Debate the optimal role of transplantation in CML

5th International Congress on Myeloproliferative Diseases and Myelodysplastic Syndromes

Confirmed Faculty

Tiziano Barbui, MD

Ospedali Riuniti di Bergamo
Bergamo, Italy

Giovanni Barosi, MD

IRCCS Policlinico San Matteo
Pavia, Italy

John M. Bennett, MD

University of Rochester
Medical Center
Rochester, New York

Francisco Cervantes, MD

Hospital Clinic, University
of Barcelona
Barcelona, Spain

Richard E. Champlin, MD

University of Texas
M.D. Anderson Cancer Center
Houston, Texas

Stefan Constantinescu, MD, PhD

Ludwig Institute for
Cancer Research
Brussels, Belgium

Jorges Cortes, MD

University of Texas
M.D. Anderson Cancer Center
Houston, Texas

Nick C.P. Cross, MA, PhD, FRCPath

University of Southampton
Salisbury, United Kingdom

Heinz Gisslinger, MD

Medical University of Vienna
Vienna, Austria

John Goldman, MD

Hammersmith Hospital
Imperial College London
London, United Kingdom

Anthony R. Green, PhD, FRCP, FRCPath

Cambridge Institute for
Medical Research
Addenbrooke's Hospital
Cambridge, United Kingdom

Francois Guilhot, MD

Université de Poitiers
Poitiers, France

Rudiger Hehlmann, MD, PhD

Klinikum Mannheim
der Universität
Heidelberg Mannheim
Mannheim, Germany

Ronald Hoffman, MD

Mount Sinai School
of Medicine
New York, New York

Hagop M. Kantarjian, MD

University of Texas
M.D. Anderson Cancer Center
Houston, Texas

Jean-Jacques Kiladjian, MD, PhD

Hopital Avicenne and
Paris 13 University
Bobigny, France

Alan F. List, MD

H. Lee Moffitt Cancer Center
and Research Institute
Tampa, Florida

Ruben A. Mesa, MD

Mayo Clinic
Rochester, Minnesota

Vesna Najfeld, MD

Mount Sinai School
of Medicine
New York, New York

Heike L. Pahl, PhD

University Hospital Freiburg
Freiburg, Germany

Josef T. Prchal, MD

University of Utah Health
Sciences Center
Salt Lake City, Utah

Jerry Radich, MD

Fred Hutchinson Cancer
Research Center
Seattle, Washington

Gail J. Roboz, MD

Weill Cornell Medical College
New York, New York

Damiano Rondelli, MD

University of Illinois
at Chicago
Chicago, Illinois

Andrew I. Schafer, MD

Weill Cornell Medical College
New York, New York

Christopher B. Schaffer, PhD

Cornell University
New York, New York

Richard T. Silver, MD, FACP

Weill Cornell Medical College
New York, New York

Radek Skoda, MD

University Hospital Basel
Basel, Switzerland

Jerry L. Spivak, MD, FACP

Johns Hopkins University
Balimore, Maryland

Ayalew Tefferi, MD

Mayo Clinic
Rochester, Minnesota

William Vainchenker, MD, PhD

Institut Gustave Roussy
Villejuif, France

Irving Weissman, MD

Stanford School of Medicine
Stanford, California

Neal S. Young, MD

National Institutes of Health
Bethesda, Maryland

Scientific Agenda

Thursday, November 5, 2009

8:00 am Welcome and Introduction
Richard T. Silver, MD, FACP

Session I: Myelodysplastic Syndromes

Chairs: *John M. Bennett, MD and Alan F. List, MD*

8:30 am	Classification, morphology, and pathogenesis of myelodysplastic diseases <i>John M. Bennett, MD</i>
9:00 am	The interface of aplastic anemia and MDS; treatment measures <i>Neal S. Young, MD</i>
9:30 am	Current treatment, including hypomethylating agents <i>Alan F. List, MD</i>
10:00 am	New drugs in MDS – Treatment of iron overload <i>Gail J. Roboz, MD</i>
10:30 am	Break
11:00 am	Which transplant and when for patients with MDS? <i>Richard E. Champlin, MD</i>
11:30 am	Keynote Address: Normal and neoplastic stem cells <i>Irving Weissman, MD</i>
12:15 pm	Discussion / Questions
12:30 pm	Lunch

Session II: Myelofibrosis

Chairs: *Ronald Hoffman, MD and Ayalew Tefferi, MD*

1:30 pm	Allogeneic transplantation in primary myelofibrosis: Relevance of the new prognostic classification <i>Francisco Cervantes, MD</i>
2:00 pm	Markers other than JAK2 and their significance <i>Heike L. Pahl, PhD</i>
2:30 pm	Abnormal stem cell trafficking in primary myelofibrosis: Pathobiology and clinical implications <i>Ronald Hoffman, MD</i>
3:00 pm	Novel therapies and assessing response in PMF <i>Ruben A. Mesa, MD</i>
3:30 pm	Break
4:00 pm	Update on JAK2 inhibitors <i>Ayalew Tefferi, MD</i>
4:30 pm	Clinical significance of endothelial lineage in progression and thrombosis <i>Giovanni Barosi, MD</i>
5:00pm	Panel discussion: Do we know enough to recommend transplantation for PMF? Chair: <i>Francisco Cervantes, MD</i> Participants : <i>Richard E. Champlin, MD, Ronald Hoffman, MD and Damiano Rondelli, MD</i>
5:30 pm	Adjourn

5th International Congress on Myeloproliferative Diseases and Myelodysplastic Syndromes

Scientific Agenda *continued* Friday, November 6, 2009

Session III: Polycythemia Vera and Essential Thrombocythemia

Chairs: *Nick C.P. Cross, MA, PhD, FRCPath and Richard T. Silver, MD, FACP*

8:30 am	Genetics of myeloproliferative disorders with emphasis on ET <i>Radek Skoda, MD</i>
9:00 am	Germline and somatic mutations in PV: Clinical significance <i>Josef T. Prchal, MD</i>
9:30 am	JAK2V617F MPD: One or several genetic events? <i>William Vainchenker, MD, PhD</i>
10:00 am	Break
10:30 am	Pegylated interferon in PV <i>Jean-Jacques Kiladjan, MD, PhD</i>
11:00 am	Genotype and phenotype in chronic myeloproliferative disorders <i>Jerry L. Spivak, MD, FACP</i>
11:30 am	Cerebral circulation in PV <i>Richard T. Silver, MD, FACP and Christopher B. Schaffer, PhD</i>
12:00 pm	Discussion / Questions

Session IV: Polycythemia Vera and Essential Thrombocythemia *cont*

Chairs: *Andrew I. Schafer and Jerry L. Spivak, MD, FACP*

1:30 pm	Inherited and acquired genetic abnormalities in myeloproliferative disorders <i>Nick C.P. Cross, MA, PhD, FRCPath</i>
2:00 pm	Molecular drug targets in myeloproliferative disorders <i>Stefan Constantinescu, MD, PhD</i>
2:30 pm	Reticulin risk factors: Is reticulin and other abnormalities increased by anagrelide? <i>Anthony R. Green, PhD, FRCP, FRCPath</i>
3:00pm	Break
3:30 pm	Risk factors for thrombosis in MPDs <i>Tiziano Barbui, MD</i>
4:00 pm	Update on clinical studies with anagrelide <i>Heinz Gisslinger, MD</i>
4:30 pm	Selected abstracts and poster review Chair: <i>Jerry L. Spivak, MD, FACP</i> Panel Members: <i>Ruben A. Mesa, MD and Vesna Najfeld, MD</i>
5:15 pm	Adjourn

November 5-7, 2009 - New York, New York
New York Marriott at The Brooklyn Bridge

Saturday, November 7, 2009

Session V: Chronic Myeloid Leukemia (CML)

Chairs: John Goldman, MD and Rudiger Hehlmann, MD, PhD

8:30 am	Update on biology and pathogenesis <i>John Goldman, MD</i>
9:00 am	Monitoring response to therapy / mechanisms of resistance <i>Jerry Radich, MD</i>
9:30 am	"Conventional" therapy of CML, including management of pregnancy in CML <i>Hagop M. Kantarjian, MD</i>
10:00 am	Break
10:30 am	Second and third generation tyrosine kinase inhibitors <i>Jorge Cortes, MD</i>
11:00 am	Treatment of accelerated and blast phase disease update <i>Rudiger Hehlmann, MD, PhD</i>
11:30 am	Phase III studies: International update <i>Francois Guilhot, MD</i>
12:00 pm	Role of transplantation in 2009 <i>Richard E. Champlin, MD</i>
12:00 pm	Discussion
1:00 pm	Adjourn

***Please visit www.imedex.com
for the most up-to-date agenda
and to register**

5th International Congress on Myeloproliferative Diseases and Myelodysplastic Syndromes

Hotel Accommodations

New York Marriott at the Brooklyn Bridge

333 Adams Street
Brooklyn, New York 11201, USA
Tel.: +1 (718) 246 7000
Fax: +1 (718) 246 0563
www.brooklynmarriott.com

Located in New York City's most celebrated neighborhood, just across the river from Manhattan sits the New York Marriott at the Brooklyn Bridge. Fresh from a 2007 expansion and renovation, the hotel boasts a relaxed but modern atmosphere with state-of-the-art amenities. The hotel sits within Renaissance Plaza, adjacent to the Metro Tech Center and surrounding universities and is a short 5 minutes from Manhattan and the Financial District, with 9 major subway lines all within one block.

For the convenience of attendees, a limited number of rooms have been reserved until October 14, 2009 at a discounted rate of \$ 299 single/double occupancy, plus tax New York State tax (8.375%), New York City tax (5%) and occupancy tax (\$3.50) per night. This rate is not guaranteed outside the congress dates or after October 14, 2009.

To reserve your room please contact New York Marriott at the Brooklyn Bridge reservations department at (888) 436 3759 or (718) 246 7000. To receive the group rate, callers must identify themselves as being with the International Congress on Myeloproliferative Diseases and Myelodysplastic Syndromes. Reservation requests received after October 14, 2009 may not be guaranteed the group rate.

Congress Location and Registration

New York Marriott at the Brooklyn Bridge
333 Adams Street
Brooklyn, New York 11201, USA
Tel.: +1 (718) 246 7000
Fax: +1 (718) 246 0563
www.brooklynmarriott.com



Imedex is a brand and assumed name used by Imedex, LLC (hereby referred to as Imedex). Imedex is solely responsible for this agenda's content. Although Imedex attempts to ensure that the information in our program is accurate and timely, matters and opinions discussed and/or presented with respect to clinical matters are those of the discussion participants only, and not necessarily those of Imedex. Moreover, although Imedex attempts to identify and integrate the most qualified medical professionals in our program, TO THE FULLEST EXTENT PERMITTED BY LAW, IMEDEX EXPRESSLY DISCLAIM ALL WARRANTIES, EITHER EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE, INCLUDING BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY, NON-INFRINGEMENT OF THIRD PARTIES' RIGHTS, AND FITNESS FOR A PARTICULAR PURPOSE, WITH RESPECT TO THE CONTENT PRESENTED. IMEDEX FURTHER MAKES NO REPRESENTATIONS OR WARRANTIES ABOUT THE ACCURACY, RELIABILITY, COMPLETENESS OR TIMELINESS OF THE CONTENT OR ANY MATERIAL PRESENTED.

In addition, the material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual's own physician.

Neither Imedex nor any of its subsidiaries or affiliates is affiliated with or formally endorsed by a medical society.

Copyright © 2008 Imedex, LLC. All rights reserved. Reproduction in whole or part is prohibited without prior written consent from Imedex and contributing faculty.

November 5-7, 2009 - New York, New York
New York Marriott at The Brooklyn Bridge

Call for Abstracts

Participants interested in presenting data should submit abstracts online at www.imedex.com by August 18, 2009. Abstracts are subject to acceptance by the Scientific Committee. Once accepted, abstracts will be published in the final course book and scheduled for oral or poster presentation.

Acceptance notifications and guidelines for poster presentations will be sent by September 15, 2009. Authors of accepted abstracts who have not registered will have until October 22, 2009 to do so at the rate of \$ 325. After this date, abstracts without registered presenters will be disregarded.

Submit your abstract online by going to www.imedex.com, selecting this Congress and following the instructions in the "Abstracts" section.

Abstract Guidelines

- Follow the online instructions
- Abstracts must be written in English
- Accepted format: Word document format, 9 point Arial font, 500 word count limit
- Use a concise title
- List affiliations of author(s) as briefly as possible, with city, state and country
- Place an asterisk (*) before the name of the presenting author
- Use standard and well-accepted abbreviations
- When using references, use standard and well-accepted formats
- Abstract content should be single-spaced, typed in lower case and contain:
 - Purpose of the study
 - Summarized description of the project
 - Results and conclusions

Submission Deadline: August 18, 2009

Submission Instructions

Go to www.imedex.com, select this Congress and follow instructions in the "**Abstracts**" section.

5th International Congress on Myeloproliferative Diseases and Myelodysplastic Syndromes

November 5-7, 2009
New York, New York
New York Marriott at
The Brooklyn Bridge

CONFERENCE REGISTRATION

A060.01

FIRST NAME _____ LAST NAME _____

DEGREE: MD PhD PharmD RN Other _____

SPECIALTY: Hematology Medical Oncology Pathology Radiation Oncology Surgery
 Other _____

EMAIL ADDRESS _____

TELEPHONE _____ FAX _____

INSTITUTE _____ DEPARTMENT _____

ADDRESS _____

CITY _____ STATE / PROVINCE _____

ZIP / POSTAL CODE _____ COUNTRY _____



Check if you require special facilities or assistance and attach a note with specific details and requirements.

REGISTRATION FEES

- \$325 Discounted**
If payment received by September 1, 2009
- \$425 Regular**
If payment received by October 29, 2009
- \$525 Full/Onsite:**
If payment received after October 29, 2009

- \$50 Group discount (physicians only)***
*cannot be combined with any other discounts
- \$199 Nurses/Residents/Students***
*proof of eligibility must accompany registration
*cannot be combined with any other discounts

PAYMENT METHOD

Credit card transactions will appear under the name Imedex Inc. on your next statement.

American Express MasterCard Visa Check in the amount of \$ _____

Card No. _____ Exp. Date: _____ / _____

Cardholder's Name: _____ Signature: _____

To pre-register, registration and payment must be received no later than October 29, 2009. Please register onsite after this date. Contact Imedex at +1 (678) 242 0906 or visit our website at www.imedex.com to ensure that the program is being held as scheduled and to confirm that the meeting is not full.

For registration fees to be refunded, written notice of cancellation must be received at meetings@imedex.com no later than October 29, 2009. The amount of registration fees remitted, minus a \$75 administrative charge, will be refunded after the Congress. Substitutions are accepted with written notification. No refunds will be made if notice is received after October 29, 2009.

Imedex does not accept responsibility for covering travel, accommodation or any other costs incurred by registrants in the rare event that this program should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation. The event agenda content is subject to change without notice.

4 EASY ways to register:



ONLINE
www.imedex.com



FAX
+1 (678) 242 0920



CALL
+1 (678) 242 0906



MAIL
Imedex®, 4325 Alexander Dr.
Alpharetta, Georgia
30022-3740, USA

Registration Fees

Discounted	\$ 325
If payment received by September 1, 2009	
Regular	\$ 425
If payment received by October 29, 2009	
Full/Onsite	\$ 525
If payment received after October 29, 2009	
Group discount (physicians only)*	-\$ 50
*cannot be combined with any other discounts	
Nurses/Residents/Students*	\$ 199

*proof of eligibility must accompany registration
*cannot be combined with any other discounts

To Register

You may register online by October 29, 2009 at www.imedex.com, by calling Imedex at +1 (678) 242 0906 or by returning the registration form in this program by mail or fax. If you mail the form, please keep a copy for your records. Registration confirmations will be issued before the meeting.

To qualify for special registration fees, registration and full payment must be received by Imedex by the dates specified.

Group Discounts

Each one of multiple registrants from the same institute or practice each receive a \$50 discount off the published registration fees, provided all registration forms and payments are received together. Only one discount will apply per physician. Discounts are not available to Nurses/Residents/Students.

Payment

To pre-register, registration and payment must be received no later than October 29, 2009. Please register onsite after this date. Contact Imedex at +1 (678) 242 0906 or visit our website at www.imedex.com to ensure the course is being held as scheduled and to confirm that the meeting is not full. Registration fees must be remitted by credit card or check. Checks should be payable to Imedex. Attendee is not registered until full payment is received.

Registration Fee Inclusions

Registration fees include admittance to all scientific sessions, Congress materials, processing of certificates of attendance or continuing medical education, and all event functions as specified in the program.

Cancellation

For registration fees to be refunded, written notice of cancellation must be received at meetings@imedex.com no later than October 29, 2009. The amount of registration fees remitted, minus a \$75 administrative charge, will be refunded after the Congress. Substitutions are accepted with written notification. No refunds will be made if notice is received after October 29, 2009.

Imedex does not accept responsibility for covering travel, accommodation or any other costs incurred by registrants in the rare event that this program should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation. The event agenda is subject to change without notice.

Congress Organizer



4325 Alexander Drive
Alpharetta, Georgia
30022-3740, USA
Tel.: +1 (770) 751 7332
Fax: +1 (770) 751 7334
Email: meetings@imedex.com
www.imedex.com